Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)
JCO Precision Oncology · 2026-06 · 10 (6)
DOI: 10.1200/po-25-01107 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-06. Verfasst von Alessandro Leonetti und 28 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Dabrafenib plus trametinib is a standard first-line treatment for BRAF V600E–mutated non–small cell lung cancer (NSCLC). The LiBRA study aimed to explore the role of liquid biopsy in detecting and monitoring BRAF V600E mutation, assessing its potential to predict treatment response and emerging resistance. MATERIALS AND METHODS This prospective multicenter study enrolled patients with BRAF V600E–mutated NSCLC treated with first-line dabrafenib plus trametinib. Plasma samples were collected at baseline (t0), after 4 weeks (t1), and longitudinally until disease progression (PD). BRAF V600E was monitored by digital droplet PCR (ddPCR). Next-generation sequencing (NGS) was performed at t0 and PD to identify resistance mechanisms. RESULTS Forty patients were enrolled. Dabrafenib plus trametinib achieved an overall response rate of 42.5%, with a median progression-free survival (PFS) and overall survival (OS) of 8.3 and 21.1 months, respectively. At t0, BRAF V600E was detectable by ddPCR in 24 (62%) of 39 patients. Among 21 shedders evaluated at t1, 17 (81%) cleared the mutation. Higher baseline BRAF V600E allele frequency was associated with shorter PFS (hazard ratio [HR], 1.09, P = .013) and OS (HR, 1.10, P = .010), whereas clearance at t1 correlated with longer PFS (8.3 v 1.4 months, P < .001) and OS (10.5 v 2.2 months, P < .001). Biological PD anticipated radiologic/clinical PD by a median of 4.9 weeks (IQR, 1.4-9.8). Baseline EGFR and MET CNVs were associated with shorter PFS and OS. Resistance mechanisms at PD included NRAS , KRAS , TP53 mutations and MET , EGFR , ERBB2 CNVs. CONCLUSION The LiBRA study supports liquid biopsy as a prognostic and monitoring tool in BRAF V600E–mutated NSCLC undergoing targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
- Department of Medicine and Surgery, University of Parma, Parma, Italy.
- Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy.
- Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
- Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- School of Medicine and Surgery, University of Milano Bicocca, Milano, Italy.
ORCID-Profile: Alessandro Leonetti, Roberta Minari, Elio Gregory Pizzutilo, Diego Luigi Cortinovis, Luca Toschi, Francesco Gelsomino, Lorenzo Belluomini, Michele Montrone, Francesca Mazzoni, Emilio Bria, Alessandro Del Conte, Fabiana Perrone, Michela Verzè, Simona D'Agnelli, Luca Boni
Zitieren
APA
Leonetti, A., Pluchino, M., Minari, R., Passiglia, F., Pizzutilo, E. G., Cortinovis, D. L., Toschi, L., Gelsomino, F., Frega, S., Metro, G., Belluomini, L., Montrone, M., Camerini, A., Bertolini, A., Baldini, E., Mazzoni, F., Bria, E., Bertolini, F., Del Conte, A., …, & Tiseo, M. (2026). Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020). JCO Precision Oncology, 10(6). https://doi.org/10.1200/po-25-01107
Vancouver
Leonetti A, Pluchino M, Minari R, Passiglia F, Pizzutilo EG, Cortinovis DL, et al. Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020). JCO Precision Oncology. 2026;10(6). doi:10.1200/po-25-01107
BibTeX
@article{Leonetti2026,
author = {Leonetti, Alessandro and Pluchino, Monica and Minari, Roberta and Passiglia, Francesco and Pizzutilo, Elio Gregory and Cortinovis, Diego Luigi and Toschi, Luca and Gelsomino, Francesco and Frega, Stefano and Metro, Giulio and Belluomini, Lorenzo and Montrone, Michele and Camerini, Andrea and Bertolini, Alessandro and Baldini, Editta and Mazzoni, Francesca and Bria, Emilio and Bertolini, Federica and Del Conte, Alessandro and Bordi, Paola and Perrone, Fabiana and Verzè, Michela and D'Agnelli, Simona and Onorini, Paola and Cosenza, Agnese and Facchinetti, Francesco and Boni, Luca and Tognetto, Michele and Tiseo, Marcello},
title = {Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {6},
doi = {10.1200/po-25-01107}
}
EUVIMED